One of them is CRISPR Therapeutics ( CRSP -0.90%). It has an approved gene-editing therapy, but investors haven't been buying ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

CRISPR Therapeutics CRSP reported first-quarter 2025 loss of $1.58 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.27 per share. In the year-ago period, the company had ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

That's only about 6 times next year's revenue estimates, and sales should continue to grow, since CRISPR Therapeutics and Vertex Pharmaceuticals have just started rolling out Casgevy. Even better ...

is arguably the best known and most effective gene editing tool - and CRISPR Therapeutics, alongside partner Vertex Pharmaceuticals Incorporated (VRTX), the Boston-based Pharma giant, secured a ...

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals (NASDAQ: VRTX) on Casgevy. Although Vertex takes a larger share of profit at 60%, this is worthwhile because Vertex has the ...

Image Source: Zacks Investment Research CRISPR Therapeutics and partner Vertex Pharmaceuticals’ VRTX CRISPR/Cas9 gene-edited therapy, Casgevy, was approved for two blood disorder indications ...